方盛制药：首个用于频发性紧张型头痛的中药创新药上市

Core Viewpoint - Fangsheng Pharmaceutical has launched "Yangxue Qufeng Zhitong Granules," the first innovative traditional Chinese medicine targeting frequent tension-type headaches, which received its drug registration certificate in June 2025 [1][2]. Market Demand for New Product - The global prevalence of tension-type headaches ranges from 11% to 45%, making it the second most common disease worldwide, with a 45.30% occurrence rate in China, affecting over 285 million patients in 2021 [2]. - Current Western treatments rely on non-steroidal anti-inflammatory drugs, which may cause adverse effects with long-term use, while the market for traditional Chinese medicine has grown from 3.9 billion yuan in 2018 to 5.3 billion yuan in 2023, indicating a lack of innovative traditional medicines specifically for frequent tension-type headaches [2]. - The development of Yangxue Qufeng Zhitong Granules began in 2014, with a total investment of approximately 27 million yuan, completing clinical trials and long-term toxicity tests [2]. Strengthening Traditional Chinese Medicine Innovation Strategy - The company's core competitive advantage lies in its new drug research and development capabilities, focusing on traditional Chinese medicine innovation, which has led to the approval and commercialization of several products [3]. - The approval of Yangxue Qufeng Zhitong Granules enhances the company's product pipeline in traditional Chinese medicine, supporting its strategy to become a health industry group centered on innovative traditional Chinese medicine [3]. - Over the past 20 years, the company has maintained a commitment to the challenging field of traditional Chinese medicine innovation, with 32 innovative traditional Chinese medicines approved nationwide in the last decade, of which 3 out of 4 approved in Hunan are owned by the company [3]. Ongoing Innovation Projects - The company has nearly 20 innovative traditional Chinese medicine projects in progress, with three 1.1 class new drugs, including Xiangqin Jiere Granules and Ziying Granules, entering clinical stages across various fields [4]. - The company is also expanding into cutting-edge areas by collaborating with top research institutions, gradually building a diversified product matrix that includes innovative traditional Chinese medicine as the main focus and chemical drugs as a supplement [4].